Requesting Antitoxin Before the Lab Can Confirm Botulism
A shared-meal cluster and a rapidly progressing descending paralysis make botulism the leading diagnosis long before any laboratory test can confirm it — and the antitoxin that treats it only works on toxin that hasn't bound yet.
T.N., a 41-year-old man, owns a small landscaping business and attended a neighborhood potluck two days ago, where he ate, among other dishes, a jar of home-canned green beans a neighbor had put up over the summer. He is generally healthy, takes no regular medications, and drinks an occasional beer on weekends. Yesterday afternoon he developed nausea and mild abdominal cramping he assumed was food-related and didn't think much of. This morning he woke with blurred, double vision, and noticed in the bathroom mirror that his left eyelid was drooping; by early afternoon his speech had become noticeably slurred and he was struggling to swallow his coffee. He drove himself to urgent care, where the slurred speech and dysphagia prompted an immediate transfer to the emergency department. On exam he has bilateral ptosis, worse on the left, diplopia on lateral gaze in both directions, dysarthria, and a weak gag; his limb strength is grossly intact today, though he reports his arms have felt “heavier” over the last hour. Deep tendon reflexes are present but slightly diminished, sensation is entirely normal throughout, and he is afebrile and mentating normally. Two other potluck attendees, reached by phone, separately report mild nausea over the same two days, though neither has developed anything resembling his neurologic symptoms yet.
The pattern — descending, cranial-nerve-first weakness with ptosis and diplopia arriving before dysarthria, dysphagia, and now early limb heaviness, normal sensation throughout, no fever, a clear GI prodrome, and a genuine shared-exposure cluster — is about as classically compatible with foodborne botulism as a presentation gets. It also overlaps meaningfully, this early, with two other real diagnoses: myasthenic crisis, which can present with fluctuating ptosis, diplopia, and bulbar weakness, and the Miller Fisher variant of Guillain-Barré syndrome, which classically pairs ophthalmoplegia with ataxia and areflexia. The interval is what separates them tonight. Neurologic onset in foodborne botulism typically falls twelve to thirty-six hours after the contaminated meal, and his cranial nerve findings began roughly forty hours after the potluck — at the long edge of that window, still comfortably inside the documented range. Miller Fisher is post-infectious: it follows its antecedent illness rather than arriving on top of it, characteristically a week or more later. His nausea and his ptosis are barely a day apart. Nothing available in the next several hours — not antibody testing, not electrodiagnostic studies, not the state laboratory's own confirmatory assay — will resolve that overlap quickly; the testing that actually confirms botulism routinely takes days to return.
At the bedside, before the state lab can weigh in
Request the antitoxin now, tonight, through the state health department to CDC — don't wait on anything else. CDC's 2021 botulism guidelines (Rao et al.) put the window at within forty-eight hours of symptom onset and ideally within twenty-four, and they say plainly that antitoxin arrests progression without reversing anything already paralyzed. Botulinum antitoxin only works on toxin that's still circulating and hasn't yet bound to a nerve terminal; once toxin binds, it blocks acetylcholine release at that terminal until the body grows a new one, and antitoxin does nothing to reverse that. Every hour we spend deciding is an hour more toxin binds irreversibly instead of getting neutralized in the bloodstream, and by our own exam, his eyes went first and his limbs are only just starting — there's real circulating toxin left to catch.
I'm not arguing this isn't likely botulism — I'm arguing it isn't proven yet, and this antitoxin isn't nothing. It's equine-derived. The fifteen-year BAT safety review (Parrera et al., 2022) puts hypersensitivity reactions somewhere between two and five percent and anaphylaxis under one and a half — small, but not nothing, and there's a formal release process to go through to even get it here. If this turns out to be Miller Fisher variant Guillain-Barré instead — which can look almost identical this early, ophthalmoplegia and areflexia together — the antitoxin does absolutely nothing for him and he's carried the risk for no benefit.
I'd want at least something that can discriminate between the two before we commit him to it, not just his eye exam.
I want to be careful with the cluster, because it is weaker than it looks. Campylobacter jejuni is the single commonest antecedent infection in Miller Fisher, it is foodborne, and CDC has worked up Campylobacter outbreaks that threw off clusters of Guillain-Barré. Two sick potluck guests do not rule your diagnosis out, and I am not going to pretend they do.
What does the work is the interval. His cranial nerves went at roughly forty hours after that meal — inside botulism's own twelve-to-thirty-six-hour window, at the long end of it. Miller Fisher follows its antecedent infection; it does not ride along with it. For this to be Miller Fisher, his nausea yesterday would have to be the trigger, and the trigger runs a week or more ahead of the neurology, not a day. That is real diagnostic information, and we have it tonight rather than in three days.
The antitoxin request itself takes real time once it's submitted, so the actual choice isn't “send it now versus send it once we're sure” — it's “send it now versus send it after losing however long the confirmatory workup takes on top of the request lag.”
Submit the request tonight, keep working the rest of the differential in parallel, and it isn't wasted effort even if it doesn't change tonight's decision.
Agreed: the antitoxin request was submitted emergently tonight through the state health department, while the parallel workup — EMG with repetitive nerve stimulation, CSF for albuminocytologic dissociation — proceeds alongside it. His airway and respiratory status are being monitored closely given the real risk of bulbar and respiratory progression.
Not agreed: whether IVIG should also be started empirically tonight in case Miller Fisher GBS is ultimately confirmed, or held entirely until a diagnosis is actually reached. The neurologist leaned toward holding it strictly, since giving both empirically would defeat the point of narrowing anything and IVIG carries its own real risks. The toxicologist was not opposed either way, since it doesn't change the antitoxin decision, and was content to let neurology own that particular call. Left genuinely open at handoff.